The impact of drugs against dementia on cognition in aging and mild cognitive impairment

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 1, 2003, Pages

  Ihl, Ralf ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; RIVASTIGMINE; TACRINE;

AGED; AGING; AUTOMATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; MEDLINE; META ANALYSIS; NEUROPSYCHOLOGICAL TEST; PARAMETER; PRIORITY JOURNAL; PROPHYLAXIS; RECALL; RECOGNITION; REM SLEEP; SENILE DEMENTIA; SIDE EFFECT; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; AGING; COGNITION; COGNITION DISORDERS; DEMENTIA; FEMALE; GALANTAMINE; GINKGO BILOBA; HUMANS; INDANS; MALE; MEDLINE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; PLANT EXTRACTS;

EID: 0042326247     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d'Arbigny P. Effect of two doses of Ginkgo biloba extract (EGb 761®) on the dual-coding test in elderly subjects. Clin Ther 1993; 15: 549-558
2. Anokhin AP, Birbaumer N, Lutzenberger W, Nikolaev A, Vogel F. Age increases brain complexity. Electroencephalogr Clin Neurophysiol 1996; 99: 63-68
3. Berger H. Über das Elektroenzephalogramm des Menschen. Arch Psychiatr Nervenkr 1931; 94: 16-60
4. Birks J, Grimley EJ, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; 4: CD001191
5. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev. 2000: CD001190
6. Burns A, Rossor M, Meeker J, Gauthier S, Petit H, Moller HJ et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244
7. Corey-Bloom J, Anand R, Veach J for the EN A 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylcholinesteraseinhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998; 1: 55-65
8. Duffy FH, Albert MS, McAnulty G. Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 1984; 16: 439-448
9. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359(9314): 1283-1290
10. Ernst E, Pittler MH. Ginkgo biloba for dementia - a systematic review of double-blind placebo controlled trials. Clin Drug Invest 1999; 4: 301-308
11. Fillit HM, Butler RN, O'Connell AW, Albert MS, Bitten JE, Cotman CW et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc 2002; 77: 681-696
12. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299-313
13. Ihl R, Brinkmeyer J. Differential diagnosis of aging, dementia of the Alzheimer type and depression with EEG-segmentation. Dement Geriatr Cogn Disord 1999; 10: 64-69
14. Jelles B, van Birgelen JH, Slaets JP, Hekster RE, Jonkman EJ, Stam CJ. Decrease of non-linear structure in the EEG of Alzheimer patients compared to healthy controls. Clin Neurophysiol 1999; 110: 1159-1167
15. Jorm AF, Christensen H, Henderson AS, Korten AE, Mackinnon AJ, Scott R. Complaints of cognitive decline in the elderly: a comparison of reports by subjects and informants in a community survey. Psychol Med 1994; 24: 365-374
16. Kanowski S, Herrmann WM, Stephan W, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary dementia of the Alzheimer type or multi-infarct-dementia. Pharmacopsychiatry 1996; 29: 47-56
17. Korten AE, Henderson AS, Christensen H, Jorm AF, Rodgers B, Jacomb P et al. A prospective study of cognitive function in the elderly. Psychol Med 1997; 27: 919-930
18. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled double-blind randomized trial of an extract of Ginkgo biloba for dementia. Journal of the American Medical Association 1997; 278: 1327-1332
19. LeBars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761® in dementia. Dement Geriatr Cogn Disord 2000; 11: 230-237
20. Lindenberger U, Baltes PB. Sensory functioning and intelligence in old age: a strong connection. Psychol Aging 1994; 9: 339-355
21. Luthringer T, d'Abigny P, Macher JP. Ginkgo biloba extract (EGb 761®), EEG and event related potentials mapping profile. In: Advances in Ginkgo biloba Extract Research, vol. 4. Effects of Ginkgo biloba Extract (EGb 761®) on Aging and Age-Related Disorders 1995
22. McCurry SM, Edland SD, Ten L, Kukull WA, Bowen JD, McCormick WC et al. The cognitive abilities screening instrument (CASI: data from a cohort of 2524 cognitively intact elderly). Int J Geriatr Psychiatry 1999; 14: 882-888
23. Meyer-Lindenberg A. The evolution of complexity in human brain development: an EEG study. Electroencephalogr Clin Neurophysiol 1996; 99: 405-411
24. Mix JA, Crews WD Jr. An examination of the efficacy of Ginkgo biloba extract EGb 761® on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med 2000; 6: 219-229
25. Mix JA, Crews WA. A double-blind, placebo controlled, randomized trial of Ginkgo biloba Extract EGb 761® in a sample of cognitively intact older adults: neuropsychological findings. Human Psychopharmacology: Clinical and Experimental 2002; 17: 267-277
26. Mundy-Castle AC. The electroencephalogram and mental activity. Electroencephalography and Clinical Neurophysiology 1957; 9: 643-655
27. Obrist WD, Busse EW. The electroencephalogram in old age. In: Wilson WP, editor. Applications of electroencephalography in psychiatry Durham, N.C.: Duke University Press, 1964: 185-205
28. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001; 4: CD001747
29. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-1415
30. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-1839
31. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991; 12: 350-355
32. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268
33. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoeffler A, Moebius HJ. Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging,; 21(1S): S275. Abstract
34. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet 2000; 355(9199): 225-228
35. Ritchie K, Ledesert B, Touchon J. Subclinical cognitive impairment: epidemiology and clinical characteristics. Compr Psychiatry 2000; 41 Suppl 1: 61-65
36. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dai-Bianco P et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. British Medical Journal 1999; 318: 633-640
37. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo- Controlled Trial. The Donepezil Study Group. Dementia 1996; 7: 293-303
38. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145
39. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984; 11: 1356-1364
40. Schaffler K, Reeh PW, Double blind study of the hypoxia protective effect of a standardized Ginkgo biloba preparation after repeated administration in healthy subjects. Arzneimittelforschung. 1985; 35: 1283-1286
41. Schredl M, Weber B, Leins ML, Heuser I. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 2001; 36: 353-361
42. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002; 288: 835-840
43. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res 1984; 4: 89-93
44. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276
45. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183-1194
46. Warot D, Lacomblez L, Danjou Ph, Weiler E, Payan C, Puech AJ. Comparaison des effets déxtraits de Ginkgo biloba sur les performances psychometrices er al mémoire chez le sujet sain. Therapie 1991; 46: 36
47. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321(7274): 1445-1449
48. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999; 14: 135-146
49. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495